- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Tetraphase Completes Enrollment of IGNITE3 Phase 3 Clinical Trial
Tetraphase Pharmaceuticals announced the completion of enrollment in IGNITE3, its ongoing phase 3 clinical trial.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced the completion of enrollment in IGNITE3, its ongoing phase 3 clinical trial.
As quoted in the press release:
The Company expects to report top-line data from this trial in the first quarter of 2018.
“We have now completed enrollment of approximately 1,200 patients in IGNITE3, well ahead of schedule, and we expect top-line data from IGNITE3 to be available during the first quarter of 2018,” said Guy Macdonald, President and CEO of Tetraphase. “In parallel, we are working to prepare a New Drug Application (NDA) for twice-daily IV eravacycline in complicated intra-abdominal infections, which will be comprised of data from the successfully completed phase 3 IGNITE1 and IGNITE4 clinical trials.
Click here to read the full press release.
Source: globenewswire.com
Outlook Reports
Featured Pharmaceutical Investing Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2369.73 | -13.12 | |
Silver | 28.28 | +0.11 | |
Copper | 4.36 | +0.03 | |
Oil | 82.80 | -2.56 | |
Heating Oil | 2.58 | -0.08 | |
Natural Gas | 1.71 | -0.03 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.